160 related articles for article (PubMed ID: 31300474)
1. Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids.
Laddha SV; da Silva EM; Robzyk K; Untch BR; Ke H; Rekhtman N; Poirier JT; Travis WD; Tang LH; Chan CS
Cancer Res; 2019 Sep; 79(17):4339-4347. PubMed ID: 31300474
[TBL] [Abstract][Full Text] [Related]
2. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
[TBL] [Abstract][Full Text] [Related]
3. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids.
Swarts DR; Scarpa A; Corbo V; Van Criekinge W; van Engeland M; Gatti G; Henfling ME; Papotti M; Perren A; Ramaekers FC; Speel EJ; Volante M
J Clin Endocrinol Metab; 2014 Feb; 99(2):E374-8. PubMed ID: 24276465
[TBL] [Abstract][Full Text] [Related]
4. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.
Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD
Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974
[TBL] [Abstract][Full Text] [Related]
5. Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.
Simbolo M; Barbi S; Fassan M; Mafficini A; Ali G; Vicentini C; Sperandio N; Corbo V; Rusev B; Mastracci L; Grillo F; Pilotto S; Pelosi G; Pelliccioni S; Lawlor RT; Tortora G; Fontanini G; Volante M; Scarpa A; Bria E
J Thorac Oncol; 2019 Sep; 14(9):1651-1661. PubMed ID: 31085341
[TBL] [Abstract][Full Text] [Related]
6. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.
Fernandez-Cuesta L; Peifer M; Lu X; Sun R; Ozretić L; Seidal D; Zander T; Leenders F; George J; Müller C; Dahmen I; Pinther B; Bosco G; Konrad K; Altmüller J; Nürnberg P; Achter V; Lang U; Schneider PM; Bogus M; Soltermann A; Brustugun OT; Helland Å; Solberg S; Lund-Iversen M; Ansén S; Stoelben E; Wright GM; Russell P; Wainer Z; Solomon B; Field JK; Hyde R; Davies MP; Heukamp LC; Petersen I; Perner S; Lovly C; Cappuzzo F; Travis WD; Wolf J; Vingron M; Brambilla E; Haas SA; Buettner R; Thomas RK
Nat Commun; 2014 Mar; 5():3518. PubMed ID: 24670920
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
9. Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology.
Cros J; Théou-Anton N; Gounant V; Nicolle R; Reyes C; Humez S; Hescot S; Thomas de Montpréville V; Guyétant S; Scoazec JY; Guyard A; de Mestier L; Brosseau S; Mordant P; Castier Y; Gentien D; Ruszniewski P; Zalcman G; Couvelard A; Cazes A
Neuroendocrinology; 2021; 111(1-2):158-169. PubMed ID: 32015233
[TBL] [Abstract][Full Text] [Related]
10. Expression of developing neural transcription factors in lung carcinoid tumors.
Endo T; Yazawa T; Shishido-Hara Y; Fujiwara M; Shimoyamada H; Ishii J; Sato H; Tachibana K; Takei H; Kondo H; Goya T; Endo S; Kamma H
Pathol Int; 2014 Aug; 64(8):365-74. PubMed ID: 25143124
[TBL] [Abstract][Full Text] [Related]
11. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis.
Sampietro G; Tomasic G; Collini P; Biganzoli E; Boracchi P; Bidoli P; Pilotti S
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):49-56. PubMed ID: 10937049
[TBL] [Abstract][Full Text] [Related]
12. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis.
Fujiwara T; Hiramatsu M; Isagawa T; Ninomiya H; Inamura K; Ishikawa S; Ushijima M; Matsuura M; Jones MH; Shimane M; Nomura H; Ishikawa Y; Aburatani H
Lung Cancer; 2012 Jan; 75(1):119-25. PubMed ID: 21737174
[TBL] [Abstract][Full Text] [Related]
13. Differential Orthopedia Homeobox expression in pulmonary carcinoids is associated with changes in DNA methylation.
Moonen L; Mangiante L; Leunissen DJG; Lap LMV; Gabriel A; Hillen LM; Roemen GM; Koch A; van Engeland M; Dingemans AC; Foll M; Alcala N; Fernandez-Cuesta L; Derks JL; Speel EM
Int J Cancer; 2022 Jun; 150(12):1987-1997. PubMed ID: 35076935
[TBL] [Abstract][Full Text] [Related]
14. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung.
Debelenko LV; Brambilla E; Agarwal SK; Swalwell JI; Kester MB; Lubensky IA; Zhuang Z; Guru SC; Manickam P; Olufemi SE; Chandrasekharappa SC; Crabtree JS; Kim YS; Heppner C; Burns AL; Spiegel AM; Marx SJ; Liotta LA; Collins FS; Travis WD; Emmert-Buck MR
Hum Mol Genet; 1997 Dec; 6(13):2285-90. PubMed ID: 9361035
[TBL] [Abstract][Full Text] [Related]
15. New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management.
Derks JL; Leblay N; Lantuejoul S; Dingemans AC; Speel EM; Fernandez-Cuesta L
J Thorac Oncol; 2018 Jun; 13(6):752-766. PubMed ID: 29454048
[TBL] [Abstract][Full Text] [Related]
16. Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors.
Asiedu MK; Thomas CF; Dong J; Schulte SC; Khadka P; Sun Z; Kosari F; Jen J; Molina J; Vasmatzis G; Kuang R; Aubry MC; Yang P; Wigle DA
Clin Cancer Res; 2018 Apr; 24(7):1691-1704. PubMed ID: 29351916
[No Abstract] [Full Text] [Related]
17. Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development.
Liu H; Kho AT; Kohane IS; Sun Y
PLoS Med; 2006 Jul; 3(7):e232. PubMed ID: 16800721
[TBL] [Abstract][Full Text] [Related]
18. Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids.
Somnay YR; Dull BZ; Eide J; Jaskula-Sztul R; Chen H
Cancer Gene Ther; 2015 Oct; 22(10):496-505. PubMed ID: 26403073
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
20. CD44 and OTP are strong prognostic markers for pulmonary carcinoids.
Swarts DR; Henfling ME; Van Neste L; van Suylen RJ; Dingemans AM; Dinjens WN; Haesevoets A; Rudelius M; Thunnissen E; Volante M; Van Criekinge W; van Engeland M; Ramaekers FC; Speel EJ
Clin Cancer Res; 2013 Apr; 19(8):2197-207. PubMed ID: 23444222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
